Free Trial

Biodesix (BDSX) News Today

Biodesix logo
$0.58 -0.02 (-2.81%)
As of 09:50 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Biodesix, Inc. stock logo
Biodesix, Inc. (NASDAQ:BDSX) Short Interest Up 29.5% in March
Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) was the recipient of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 1,260,000 shares, a growth of 29.5% from the February 28th total of 973,200 shares. Based on an average trading volume of 417,700 shares, the short-interest ratio is currently 3.0 days. Currently, 2.8% of the shares of the company are sold short.
Biodesix, Inc. stock logo
Biodesix, Inc. (NASDAQ:BDSX) Shares Acquired by AIGH Capital Management LLC
AIGH Capital Management LLC increased its holdings in shares of Biodesix, Inc. (NASDAQ:BDSX - Free Report) by 8.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,179,812 shares of the company's stock aft
Biodesix, Inc. stock logo
Perkins Capital Management Inc. Increases Holdings in Biodesix, Inc. (NASDAQ:BDSX)
Perkins Capital Management Inc. grew its stake in Biodesix, Inc. (NASDAQ:BDSX - Free Report) by 46.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,060,211 shares of the company's stock after acquirin
Biodesix, Inc. stock logo
Biodesix, Inc. (NASDAQ:BDSX) Short Interest Up 24.6% in February
Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) was the target of a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 973,200 shares, a growth of 24.6% from the February 13th total of 781,300 shares. Approximately 2.2% of the company's shares are sold short. Based on an average daily volume of 428,500 shares, the short-interest ratio is currently 2.3 days.
Biodesix, Inc. stock logo
What is William Blair's Forecast for Biodesix Q1 Earnings?
Biodesix, Inc. (NASDAQ:BDSX - Free Report) - Equities researchers at William Blair issued their Q1 2025 earnings per share (EPS) estimates for shares of Biodesix in a research note issued to investors on Tuesday, March 4th. William Blair analyst A. Brackmann anticipates that the company will earn
Biodesix, Inc. stock logo
Research Analysts Set Expectations for Biodesix Q1 Earnings
Biodesix, Inc. (NASDAQ:BDSX - Free Report) - Equities researchers at William Blair issued their Q1 2026 earnings estimates for Biodesix in a research report issued to clients and investors on Tuesday, March 4th. William Blair analyst A. Brackmann forecasts that the company will post earnings of (
Scotiabank Keeps Their Buy Rating on Biodesix (BDSX)
Biodesix reports Q4 EPS (6c) vs. (10c) last year
Biodesix, Inc. stock logo
Biodesix (NASDAQ:BDSX) Earns "Outperform" Rating from William Blair
William Blair reaffirmed an "outperform" rating on shares of Biodesix in a report on Tuesday.
Biodesix, Inc. stock logo
Biodesix (NASDAQ:BDSX) Posts Earnings Results, Beats Estimates By $0.01 EPS
Biodesix (NASDAQ:BDSX - Get Free Report) issued its earnings results on Monday. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%.
Biodesix, Inc. stock logo
Biodesix (BDSX) Expected to Announce Earnings on Monday
Biodesix (NASDAQ:BDSX) will be releasing earnings after the market closes on Monday, March 3. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=667161)
Biodesix, Inc. stock logo
Insider Selling: Biodesix, Inc. (NASDAQ:BDSX) Insider Sells 16,748 Shares of Stock
Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) insider Gary Anthony Pestano sold 16,748 shares of the stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total value of $15,408.16. Following the sale, the insider now directly owns 156,008 shares of the company's stock, valued at approximately $143,527.36. This trade represents a 9.69 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Biodesix, Inc. stock logo
Robin Harper Cowie Sells 24,664 Shares of Biodesix, Inc. (NASDAQ:BDSX) Stock
Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) CFO Robin Harper Cowie sold 24,664 shares of Biodesix stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total value of $22,690.88. Following the completion of the sale, the chief financial officer now owns 246,460 shares of the company's stock, valued at approximately $226,743.20. The trade was a 9.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Biodesix, Inc. stock logo
Biodesix, Inc. (NASDAQ:BDSX) CEO Scott Hutton Sells 83,660 Shares
Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) CEO Scott Hutton sold 83,660 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total transaction of $76,967.20. Following the completion of the sale, the chief executive officer now directly owns 701,947 shares of the company's stock, valued at $645,791.24. This trade represents a 10.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Biodesix, Inc. stock logo
Short Interest in Biodesix, Inc. (NASDAQ:BDSX) Declines By 7.4%
Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) was the target of a significant drop in short interest in January. As of January 15th, there was short interest totalling 836,600 shares, a drop of 7.4% from the December 31st total of 903,100 shares. Based on an average trading volume of 420,900 shares, the short-interest ratio is presently 2.0 days.
Biodesix, Inc. stock logo
Short Interest in Biodesix, Inc. (NASDAQ:BDSX) Drops By 7.4%
Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) was the target of a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 836,600 shares, a decrease of 7.4% from the December 15th total of 903,100 shares. Based on an average daily volume of 420,900 shares, the short-interest ratio is presently 2.0 days.
Lake Street Sticks to Their Buy Rating for Biodesix (BDSX)
Craig-Hallum Gives a Buy Rating to Biodesix (BDSX)
Biodesix, Inc. stock logo
Short Interest in Biodesix, Inc. (NASDAQ:BDSX) Expands By 44.7%
Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) saw a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 903,100 shares, an increase of 44.7% from the November 30th total of 624,200 shares. Based on an average daily trading volume, of 395,100 shares, the short-interest ratio is presently 2.3 days.
Biodesix, Inc. stock logo
Wilmington Savings Fund Society FSB Takes Position in Biodesix, Inc. (NASDAQ:BDSX)
Wilmington Savings Fund Society FSB acquired a new position in Biodesix, Inc. (NASDAQ:BDSX - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 6,095,034 shares of the company's stock, valued at approximately $10,849,00
Biodesix, Inc. (BDSX)
Insider Buys Additional US$234k In Biodesix Stock
Biodesix, Inc. stock logo
Biodesix, Inc. (NASDAQ:BDSX) Receives Consensus Rating of "Buy" from Analysts
Shares of Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) have received an average rating of "Buy" from the seven brokerages that are covering the stock, Marketbeat reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages
Biodesix, Inc. stock logo
Biodesix (NASDAQ:BDSX) Issues Earnings Results, Beats Expectations By $0.01 EPS
Biodesix (NASDAQ:BDSX - Get Free Report) posted its quarterly earnings results on Friday. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. Biodesix had a negative net margin of 73.08% and a negative return on equity of 505.95%. The firm had revenue of $18.15 million for the quarter, compared to the consensus estimate of $18.45 million. During the same period last year, the firm posted ($0.12) earnings per share.
Biodesix Reports Strong Q3 2024 Growth in Diagnostics
Biodesix files to sell 62.2M shares of common stock for holders
Biodesix: Poised for Recovery and Growth Amid Temporary Setbacks
Craig-Hallum Sticks to Its Buy Rating for Biodesix (BDSX)
Biodesix, Inc. stock logo
Biodesix (BDSX) Set to Announce Quarterly Earnings on Friday
Biodesix (NASDAQ:BDSX) will be releasing earnings before the market opens on Friday, November 1, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=637164)
Biodesix, Inc. stock logo
Biodesix, Inc. (NASDAQ:BDSX) Short Interest Up 29.3% in September
Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) was the recipient of a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 419,700 shares, an increase of 29.3% from the September 15th total of 324,700 shares. Based on an average daily volume of 128,000 shares, the short-interest ratio is presently 3.3 days.
Biodesix, Inc. stock logo
Perceptive Advisors LLC Takes $3.33 Million Position in Biodesix, Inc. (NASDAQ:BDSX)
Perceptive Advisors LLC purchased a new position in shares of Biodesix, Inc. (NASDAQ:BDSX - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,173,880 shares of the company's st
Biodesix, Inc. stock logo
Farallon Capital Management LLC Purchases New Stake in Biodesix, Inc. (NASDAQ:BDSX)
Farallon Capital Management LLC purchased a new stake in shares of Biodesix, Inc. (NASDAQ:BDSX - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 1,878,175 shares of the company's stock, valued at approximately $2,874,000. Fara
Craig-Hallum Keeps Their Buy Rating on Biodesix (BDSX)
Biodesix, Inc. stock logo
Short Interest in Biodesix, Inc. (NASDAQ:BDSX) Declines By 15.6%
Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) was the recipient of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totalling 357,500 shares, a decrease of 15.6% from the August 15th total of 423,500 shares. Based on an average daily volume of 143,400 shares, the short-interest ratio is presently 2.5 days.
Remove Ads
Get Biodesix News Delivered to You Automatically

Sign up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter.

BDSX Media Mentions By Week

BDSX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BDSX
News Sentiment

1.88

0.61

Average
Medical
News Sentiment

BDSX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BDSX Articles
This Week

2

1

BDSX Articles
Average Week

Remove Ads
Get Biodesix News Delivered to You Automatically

Sign up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:BDSX) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners